- Home
- DRTS vs ANNX Comparison
DRTS vs ANNX Comparison
Compare DRTS & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRTS
- ANNX
- Stock Information
- Founded
- DRTS 2015
- ANNX 2011
- Country
- DRTS Israel
- ANNX United States
- Employees
- DRTS N/A
- ANNX N/A
- Industry
- DRTS Medical/Dental Instruments
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- DRTS Health Care
- ANNX Health Care
- Exchange
- DRTS Nasdaq
- ANNX Nasdaq
- Market Cap
- DRTS 252.8M
- ANNX 252.3M
- IPO Year
- DRTS N/A
- ANNX 2020
- Fundamental
- Price
- DRTS $3.12
- ANNX $2.40
- Analyst Decision
- DRTS Strong Buy
- ANNX Strong Buy
- Analyst Count
- DRTS 2
- ANNX 4
- Target Price
- DRTS $8.00
- ANNX $12.50
- AVG Volume (30 Days)
- DRTS 43.2K
- ANNX 1.3M
- Earning Date
- DRTS 08-13-2025
- ANNX 08-11-2025
- Dividend Yield
- DRTS N/A
- ANNX N/A
- EPS Growth
- DRTS N/A
- ANNX N/A
- EPS
- DRTS N/A
- ANNX N/A
- Revenue
- DRTS N/A
- ANNX N/A
- Revenue This Year
- DRTS N/A
- ANNX N/A
- Revenue Next Year
- DRTS N/A
- ANNX N/A
- P/E Ratio
- DRTS N/A
- ANNX N/A
- Revenue Growth
- DRTS N/A
- ANNX N/A
- 52 Week Low
- DRTS $1.93
- ANNX $1.29
- 52 Week High
- DRTS $4.39
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- DRTS 59.34
- ANNX 56.48
- Support Level
- DRTS $2.91
- ANNX $2.32
- Resistance Level
- DRTS $3.20
- ANNX $2.49
- Average True Range (ATR)
- DRTS 0.16
- ANNX 0.18
- MACD
- DRTS -0.00
- ANNX -0.03
- Stochastic Oscillator
- DRTS 68.70
- ANNX 35.09
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.